CINCINNATI--(BUSINESS WIRE)--May 3, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been
added to Mergent's Dividend Achievers Index(TM) for 2006. This index
is made up of just 3% of U.S. publicly traded companies with the most
consistent records of annual dividend increases.
Quoting from Mergent's correspondence, "This designation means
that you (Meridian Bioscience, Inc.) are part of an elite class of
companies that have successfully delivered dividend increases to
shareholders for 10 or more consecutive years. Dividend Achievers are
strong companies with the potential to outperform broad based indices
over the long term. In fact, over the past 10 years through 2005,
Mergent's Dividend Achievers Index has outperformed the S&P 500 Index
by an annualized rate of 1.8% per year."
William J. Motto, Chairman and Chief Executive Officer, stated,
"We are very pleased to be included in the Mergent's Dividend
Achievers Index(TM) for the third year in a row. Our long-standing
cash dividend policy has served shareholders well with fourteen
increases during the past sixteen years. Our current indicated annual
cash dividend rate is $0.46 per share. With our strong cash flow from
operations, we are able to internally fund the company's growth and
concurrently payout between 75% and 85% of our net earnings in cash
dividends to shareholders."
Meridian is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and
offers biopharmaceutical enabling technologies. Utilizing a variety of
methods, these products provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral, and respiratory infections. Meridian
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents and specialty biologicals along with
proteins and other biologicals used by biopharmaceutical companies
engaged in research for new drugs and vaccines. The Company markets
its products to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices and diagnostics
manufacturers in more than 60 countries around the world. The
Company's shares are traded through Nasdaq's National Market, symbol
VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
SOURCE: Meridian Bioscience, Inc.